Immune pathway may promote the progression of oral precancerous lesions
View as a Web Page
News Medical
 
  Oncology Oncology logo  
  The latest oncology news from News Medical  
 More than 50 million Americans lack local radiation cancer treatmentMore than 50 million Americans lack local radiation cancer treatment
 
The disappearance of radiation oncology clinics threatens cancer care access for over 50 million Americans, with rural areas facing the greatest impact.
 
 
 Immune pathway may promote the progression of oral precancerous lesionsImmune pathway may promote the progression of oral precancerous lesions
 
Researchers at The University of Texas MD Anderson Cancer Center identified an immune pathway that may promote the progression of oral precancerous lesions into head and neck squamous cell carcinoma.
 
   Self-assembling antibody drugs successfully target multiple cancer receptorsSelf-assembling antibody drugs successfully target multiple cancer receptors
 
Modern anticancer medications that combine tumor-fighting drugs with proteins that specifically target cancer cells are a relatively new class of drug, often given to patients for whom standard chemotherapy has not worked.
 
   AI model predicts effective immunotherapy combinations for liver cancerAI model predicts effective immunotherapy combinations for liver cancer
 
Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to predict which patients with a primary liver cancer called hepatocellular carcinoma (HCC) would most benefit from combination treatment using immunotherapy and a targeted therapy that blocks the growth signals that the tumor depends on.
 
   Experimental drug shows promise against NRAS-driven melanomaExperimental drug shows promise against NRAS-driven melanoma
 
A research team from Huntsman Cancer Institute at the University of Utah (the U) reports that a groundbreaking pathway-targeted therapy could be an effective treatment for certain melanoma patients and fill an unmet clinical need for patients with advanced disease.
 
 New biological feedback loop helps the immune system attack colorectal cancers
 
New biological feedback loop helps the immune system attack colorectal cancersA subset of cancers, known as microsatellite instability (MSI) and deficient DNA mismatch repair (dMMR) cancers, are more visible to the immune system than others.
 
 
 Ketogenic diet may increase small intestine cancer risk in mice
 
Ketogenic diet may increase small intestine cancer risk in miceA high-fat, low-carbohydrate diet, also called a ketogenic diet, can help some people lose weight by forcing their bodies to burn fat for fuel instead of sugar.
 
 
 Oral drug avatrombopag reduces chemotherapy treatment delays, trial finds
 
Oral drug avatrombopag reduces chemotherapy treatment delays, trial findsIn a phase 2 trial of patients with gastrointestinal cancers, avatrombopag helped 70% of those receiving chemotherapy to stay on treatment schedule, compared with 17% receiving placebo.
 
 
 Unlocking the potential of organoids in modern drug discovery
 
Unlocking the potential of organoids in modern drug discoveryExplore how organoids are unlocking new possibilities in modern drug discovery by improving disease modelling within DMTA-driven research workflows.
 
 
 Experimental KRAS vaccine safely generates durable immune response against pancreatic cancer
 
Experimental KRAS vaccine safely generates durable immune response against pancreatic cancerResearchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer report that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.
 
 
 Targeted nanoparticles destroy tumor cells by triggering cuproptosis
 
Targeted nanoparticles destroy tumor cells by triggering cuproptosisA promising cancer treatment strategy called cuproptosis, which uses copper-dependent cell death to eliminate tumor cells, faces a major challenge: many approaches require adding external copper, potentially increasing toxicity beyond the tumor.
 
 
 LIG1 loss reveals new treatment strategy for aggressive breast cancer
 
LIG1 loss reveals new treatment strategy for aggressive breast cancerLoss of one copy of the DNA Ligase I (LIG1) gene in triple-negative breast cancers (TNBC) with TP53 mutations confers resistance to chemotherapy, but researchers at Baylor College of Medicine and collaborating institutions have identified a vulnerability in these cells and used it to their advantage.
 
 
 Weill Cornell Medicine receives DoD grant to target triple-negative breast cancer
 
Weill Cornell Medicine receives DoD grant to target triple-negative breast cancerWeill Cornell Medicine has received a $2.5 million, three-year grant from the Department of Defense (DoD) to develop therapies with fewer side effects for triple-negative breast cancer, one of the most aggressive and difficult-to-treat breast cancers.
 
 
 Researchers uncover new T cell attack mechanism against acute myeloid leukemia
 
Researchers at The University of Texas MD Anderson Cancer Center have discovered a new way in which T cells attack acute myeloid leukemia (AML) cells, which may help explain why AML is particularly sensitive to immune-based treatments and could guide the development of future cancer immunotherapies.
 
 
 Exercise oncology could unlock new therapeutic pathways against cancer
 
Regular exercise is associated with improved outcomes for many patients with cancer, yet those with advanced disease may be unable to participate in exercise-based interventions.
 
 
 Study highlights communication gaps between cancer survivors and providers on cannabis
 
For many cancer survivors, cannabis has become part of how they manage symptoms such as pain, nausea and anxiety.
 
 
 New ctDNA blood test improves personalized prostate cancer treatment
 
A noninvasive DNA blood test can identify metastatic castration-resistant prostate cancer (mCRPC) patients who are most likely to benefit from 223Ra radiopharmaceutical therapy and monitor their progress throughout treatment, according to new research published in the July issue of The Journal of Nuclear Medicine.
 
Facebook X Instagram LinkedIn Vimeo
Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd., NEO, 9 Charlotte St, Manchester, M1 4ET, UK

Manchester | Sydney | Boston

Copyright © 2000-2026